Cargando…

An ETP model (exclusion-tolerance-progression) for multi drug resistance

BACKGROUND: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of sensitive...

Descripción completa

Detalles Bibliográficos
Autor principal: Kannan, Subburaj
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131929/
https://www.ncbi.nlm.nih.gov/pubmed/15857507
http://dx.doi.org/10.1186/1742-4682-2-17
_version_ 1782123961983696896
author Kannan, Subburaj
author_facet Kannan, Subburaj
author_sort Kannan, Subburaj
collection PubMed
description BACKGROUND: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of sensitive to resistant cell populations. RESULTS: Based on findings from clinical and experimental studies, a unifying model is proposed to delineate the potential mechanism by which tumor cells progress towards multi drug resistance, resulting in failure of chemotherapy. CONCLUSION: It is suggested that the evolution of multi drug resistance is a developmentally orchestrated event. Identifying stage-specific time windows during this process would help to identify valid therapeutic targets for the effective elimination of malignancy.
format Text
id pubmed-1131929
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11319292005-05-20 An ETP model (exclusion-tolerance-progression) for multi drug resistance Kannan, Subburaj Theor Biol Med Model Research BACKGROUND: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of sensitive to resistant cell populations. RESULTS: Based on findings from clinical and experimental studies, a unifying model is proposed to delineate the potential mechanism by which tumor cells progress towards multi drug resistance, resulting in failure of chemotherapy. CONCLUSION: It is suggested that the evolution of multi drug resistance is a developmentally orchestrated event. Identifying stage-specific time windows during this process would help to identify valid therapeutic targets for the effective elimination of malignancy. BioMed Central 2005-04-27 /pmc/articles/PMC1131929/ /pubmed/15857507 http://dx.doi.org/10.1186/1742-4682-2-17 Text en Copyright © 2005 Kannan; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kannan, Subburaj
An ETP model (exclusion-tolerance-progression) for multi drug resistance
title An ETP model (exclusion-tolerance-progression) for multi drug resistance
title_full An ETP model (exclusion-tolerance-progression) for multi drug resistance
title_fullStr An ETP model (exclusion-tolerance-progression) for multi drug resistance
title_full_unstemmed An ETP model (exclusion-tolerance-progression) for multi drug resistance
title_short An ETP model (exclusion-tolerance-progression) for multi drug resistance
title_sort etp model (exclusion-tolerance-progression) for multi drug resistance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131929/
https://www.ncbi.nlm.nih.gov/pubmed/15857507
http://dx.doi.org/10.1186/1742-4682-2-17
work_keys_str_mv AT kannansubburaj anetpmodelexclusiontoleranceprogressionformultidrugresistance
AT kannansubburaj etpmodelexclusiontoleranceprogressionformultidrugresistance